JP2024527020A5 - - Google Patents

Info

Publication number
JP2024527020A5
JP2024527020A5 JP2024504772A JP2024504772A JP2024527020A5 JP 2024527020 A5 JP2024527020 A5 JP 2024527020A5 JP 2024504772 A JP2024504772 A JP 2024504772A JP 2024504772 A JP2024504772 A JP 2024504772A JP 2024527020 A5 JP2024527020 A5 JP 2024527020A5
Authority
JP
Japan
Prior art keywords
terminus
antigen
domain
region
peptide linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/071060 external-priority patent/WO2023006809A1/en
Publication of JP2024527020A publication Critical patent/JP2024527020A/ja
Publication of JP2024527020A5 publication Critical patent/JP2024527020A5/ja
Pending legal-status Critical Current

Links

JP2024504772A 2021-07-27 2022-07-27 抗原結合分子の組合せ Pending JP2024527020A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21187924 2021-07-27
EP21187924.2 2021-07-27
PCT/EP2022/071060 WO2023006809A1 (en) 2021-07-27 2022-07-27 Combinations of antigen binding molecules

Publications (2)

Publication Number Publication Date
JP2024527020A JP2024527020A (ja) 2024-07-19
JP2024527020A5 true JP2024527020A5 (https=) 2025-09-02

Family

ID=77103832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504772A Pending JP2024527020A (ja) 2021-07-27 2022-07-27 抗原結合分子の組合せ

Country Status (7)

Country Link
US (1) US20250101103A1 (https=)
EP (1) EP4377347A1 (https=)
JP (1) JP2024527020A (https=)
CN (1) CN117715939A (https=)
AU (1) AU2022318255A1 (https=)
CA (1) CA3227537A1 (https=)
WO (1) WO2023006809A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025237931A1 (en) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
CA2861003C (en) 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
PE20171324A1 (es) * 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
CN111246885B (zh) 2017-10-20 2024-06-11 豪夫迈·罗氏有限公司 从单特异性抗体生成多特异性抗体的方法
JP7542438B2 (ja) * 2017-11-21 2024-08-30 ノバルティス アーゲー 腫瘍関連抗原に対する三重特異性結合分子及びその使用
KR20200118423A (ko) * 2018-01-08 2020-10-15 난징 레전드 바이오테크 씨오., 엘티디. 다중특이성 항원 결합 단백질 및 이의 사용 방법
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
US20210269547A1 (en) 2018-07-02 2021-09-02 The General Hospital Corporation Antibody tumor-targeting assembly complexes
EP3827019A1 (en) * 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020115115A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
CN113767114A (zh) 2019-04-25 2021-12-07 豪夫迈·罗氏有限公司 半衰期延长的可活化治疗性多特异性多肽
TWI911155B (zh) 2019-04-25 2026-01-11 瑞士商赫孚孟拉羅股份公司 藉由多肽鏈交換活化之治療性多特異性多肽
JP7812230B2 (ja) 2019-04-25 2026-02-09 エフ. ホフマン-ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
AU2020267131A1 (en) 2019-05-02 2021-11-25 Revitope Limited TEAC and ATTAC immunooncology compositions and methods
US12077603B2 (en) * 2019-08-15 2024-09-03 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon

Similar Documents

Publication Publication Date Title
JP7457764B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
JP2024527020A5 (https=)
Deyev et al. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design
JP2020517287A5 (https=)
JP2023548443A5 (https=)
US20040220388A1 (en) Novel heterodimeric fusion proteins
JP2021525530A5 (https=)
JP2017504578A5 (https=)
JP2021515798A5 (https=)
JP2023509212A5 (https=)
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
JP2021159081A5 (https=)
JP2020506898A5 (https=)
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2016536322A5 (https=)
JP2014158485A5 (https=)
SI2573121T1 (en) Antibodies that bind IL-4 and/or IL-13 and their uses
JP2024113040A5 (https=)
JP2022532370A5 (https=)
CN116925215A (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2019535315A5 (https=)
JP2022504826A5 (https=)
JP2025160226A5 (https=)
JP2023544211A5 (https=)
JP2023552462A5 (https=)